Bill
S 2372
Overview: S 2372 is a bill introduced in the Senate titled the "340B PATIENTS Act of 2025".Purpose and Intent: The bill aims to address concerns regarding the 340B drug pricing pro
Overview: S 2372 is a bill introduced in the Senate titled the "340B PATIENTS Act of 2025".
Purpose and Intent: The bill aims to address concerns regarding the 340B drug pricing program, which requires drug manufacturers to provide discounted drugs to certain healthcare providers, by introducing new transparency and oversight measures.
Key Provisions:
- Requires drug manufacturers to report certain information about 340B drug sales and discounts
- Establishes a dispute resolution process for disagreements between 340B covered entities and drug manufacturers
- Directs the Government Accountability Office to conduct a study on the 340B program's impact on patient access and drug prices
Affected Parties and Impacts:
- 340B covered entities, such as certain hospitals and clinics, would be affected by the new reporting and dispute resolution requirements
- Drug manufacturers would be required to provide more transparency and comply with the new regulations
- Patients may be impacted by changes to the 340B program's effect on drug prices and access
Procedural and Timeline Considerations:
- The bill has been introduced in the Senate and is currently in the legislative process
- If passed by Congress and signed into law, the new requirements and oversight measures would be implemented, potentially leading to changes in the 340B program
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
